{"id":80765,"date":"2026-05-01T13:17:18","date_gmt":"2026-05-01T07:47:18","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=80765"},"modified":"2026-05-01T13:17:20","modified_gmt":"2026-05-01T07:47:20","slug":"syngene-international-limited-q4-fy26-results-pat-147-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/","title":{"rendered":"PAT Rs 147.90 Crore | Syngene International Q4 FY26 Results"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p>Syngene International announced its Q4 FY26 financial results on April 29, 2026, reporting PAT of Rs 147.90 crore, a 19.3 percent year-on-year decline, as the Contract Research and CDMO company delivered its January to March 2026 quarter earnings. Syngene International Q4 FY26 results are closely tracked by investors as a key indicator of the company&#8217;s performance trajectory. This article covers the Syngene International Q4 FY26 financial highlights, performance analysis, full year FY26 summary, management outlook, and frequently asked questions on Syngene International Q4 results.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#Syngene_International_Q4_FY26_Financial_Highlights\" title=\"Syngene International Q4 FY26 Financial Highlights\">Syngene International Q4 FY26 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#Syngene_International_Q4_FY26_Performance_Analysis\" title=\"Syngene International Q4 FY26 Performance Analysis\">Syngene International Q4 FY26 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#Syngene_International_Full_Year_FY26_Business_Summary\" title=\"Syngene International Full Year FY26 Business Summary\">Syngene International Full Year FY26 Business Summary<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#Syngene_International_Q4_FY26_Outlook_and_FY27_Priorities\" title=\"Syngene International Q4 FY26 Outlook and FY27 Priorities\">Syngene International Q4 FY26 Outlook and FY27 Priorities<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#Frequently_Asked_Questions_on_Syngene_International_Q4_FY26_Results\" title=\"Frequently Asked Questions on Syngene International Q4 FY26 Results\">Frequently Asked Questions on Syngene International Q4 FY26 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#What_were_the_Syngene_International_Q4_FY26_results\" title=\"What were the Syngene International Q4 FY26 results?\">What were the Syngene International Q4 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#What_was_Syngene_International_Q4_FY26_PAT\" title=\"What was Syngene International Q4 FY26 PAT?\">What was Syngene International Q4 FY26 PAT?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#What_was_Syngene_International_Q4_FY26_revenue\" title=\"What was Syngene International Q4 FY26 revenue?\">What was Syngene International Q4 FY26 revenue?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#Did_Syngene_International_declare_a_dividend_after_Q4_FY26_results\" title=\"Did Syngene International declare a dividend after Q4 FY26 results?\">Did Syngene International declare a dividend after Q4 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#What_is_the_outlook_for_Syngene_International_after_Q4_FY26\" title=\"What is the outlook for Syngene International after Q4 FY26?\">What is the outlook for Syngene International after Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#How_did_Syngene_International_Q4_FY26_compare_year_on_year\" title=\"How did Syngene International Q4 FY26 compare year on year?\">How did Syngene International Q4 FY26 compare year on year?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#What_sector_does_Syngene_International_operate_in\" title=\"What sector does Syngene International operate in?\">What sector does Syngene International operate in?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#Is_Syngene_International_a_good_investment_after_Q4_FY26_results\" title=\"Is Syngene International a good investment after Q4 FY26 results?\">Is Syngene International a good investment after Q4 FY26 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-limited-q4-fy26-results-pat-147-crore\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Syngene_International_Q4_FY26_Financial_Highlights\"><\/span><strong>Syngene International Q4 FY26 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Syngene International reported Q4 FY26 consolidated PAT of Rs 147.90 crore (after exceptional items), a 19.3 percent year-on-year decline from Rs 183.30 crore in Q4 FY25. Q4 FY26 revenue was Rs 1,037 crore. EBITDA margin stood at 30.8 percent. The company completed 14 audits in Q4 and received GCP-NABL accreditation. Kiran Mazumdar-Shaw transitioned to Executive Chairperson from April 2026. Siddharth Mittal appointed as MD and CEO from July 2026.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Q4 FY26<\/th>\n<th>Q4 FY25<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<tr>\n<td>Revenue \/ Total Income<\/td>\n<td>Rs 1,037 crore<\/td>\n<td>Refer NSE\/BSE filing<\/td>\n<td>Grew YoY<\/td>\n<\/tr>\n<tr>\n<td>PAT<\/td>\n<td>Rs 147.90 crore<\/td>\n<td>Refer NSE\/BSE filing<\/td>\n<td>Lower 19.3 percent YoY<\/td>\n<\/tr>\n<tr>\n<td>Full Year FY26 PAT<\/td>\n<td>Refer annual filing<\/td>\n<td>Refer filing<\/td>\n<td>As reported<\/td>\n<\/tr>\n<tr>\n<td>Dividend (FY26)<\/td>\n<td>Not declared<\/td>\n<td>Refer filing<\/td>\n<td>FY26 final<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Also Read:<\/strong> <a href=\"https:\/\/univest.in\/blogs-2\/bhansali-engineering-polymers-q4-fy26-results-pat-51-crore\/\">Bhansali Engineering Polymers Q4 FY26 Results<\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Syngene_International_Q4_FY26_Performance_Analysis\"><\/span><strong>Syngene International Q4 FY26 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Syngene International Q4 FY26 PAT decline of 19.3 percent reflects the company&#8217;s continued heavy investment in biologics, ADC (Antibody-Drug Conjugate), and CDMO capacity expansion, which has increased depreciation and amortisation costs. The company completed 85 regulatory audits for FY26 and was included in the S and P Global Sustainability Yearbook 2026 top 10 life sciences companies.<\/p>\n<p>Syngene International Q4 FY26 EBITDA margin at 30.8 percent remained healthy despite investment headwinds. Revenue grew modestly as new biologics and ADC CDMO capacities at the Mangaluru facility begin ramping up.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Syngene_International_Full_Year_FY26_Business_Summary\"><\/span><strong>Syngene International Full Year FY26 Business Summary<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>For FY26, Syngene reported revenue of Rs 3,738.7 crore (up 2.6 percent YoY) and EBITDA of Rs 989.1 crore (down 11.2 percent) with margin at 26 percent versus 30 percent in FY25. Biologics and ADC infrastructure investments are the primary reason for margin compression.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Syngene_International_Q4_FY26_Outlook_and_FY27_Priorities\"><\/span><strong>Syngene International Q4 FY26 Outlook and FY27 Priorities<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Syngene International FY27 outlook is positive as biologics and ADC capacities ramp up under new CEO Siddharth Mittal. Recovery in global biopharma outsourcing demand and Syngene&#8217;s expanded capabilities set up stronger FY27 revenue growth.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and insightful research pieces!<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Syngene International Q4 FY26 results<\/strong> provide investors with the company&#8217;s January to March 2026 performance data. Syngene International Q4 FY26 PAT of Rs 147.90 crore reflects the operational performance in the Contract Research and CDMO sector. Investors tracking <strong>Syngene International Q4<\/strong> results should review the complete audited financials on NSE and BSE exchange filings before making any investment decision. Syngene International Q4 FY26 is an important milestone in the company&#8217;s annual earnings calendar.<\/p>\n<p><em>This article on Syngene International Q4 FY26 results is for informational and educational purposes only. It is not investment advice. Please consult a SEBI registered investment advisor before making any investment decision. Past performance is not indicative of future results.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Syngene_International_Q4_FY26_Results\"><\/span><strong>Frequently Asked Questions on Syngene International Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Syngene_International_Q4_FY26_results\"><\/span><strong>What were the Syngene International Q4 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Syngene International Q4 FY26 results were announced on April 29, 2026. The company reported PAT of Rs 147.90 crore for the January to March 2026 quarter. Syngene International Q4 FY26 details are in the official NSE and BSE exchange filings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Syngene_International_Q4_FY26_PAT\"><\/span><strong>What was Syngene International Q4 FY26 PAT?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Syngene International Q4 FY26 PAT was Rs 147.90 crore, lower 19.3 percent YoY. The Syngene International Q4 FY26 results were announced on April 29, 2026, at the board of directors meeting to approve audited financials.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Syngene_International_Q4_FY26_revenue\"><\/span><strong>What was Syngene International Q4 FY26 revenue?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Syngene International Q4 FY26 revenue was Rs 1,037 crore. Investors should refer to the NSE and BSE exchange filing for the full audited Syngene International Q4 FY26 revenue breakdown and segmental performance data.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Syngene_International_declare_a_dividend_after_Q4_FY26_results\"><\/span><strong>Did Syngene International declare a dividend after Q4 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Syngene International did not declare a dividend in the Q4 FY26 results announcement. Refer to the official exchange filing for confirmation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_outlook_for_Syngene_International_after_Q4_FY26\"><\/span><strong>What is the outlook for Syngene International after Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Syngene International FY27 outlook is positive as biologics and ADC capacities ramp up under new CEO Siddharth Mittal. Recovery in global biopharma outsourcing demand and Syngene&#8217;s expanded capabilities set up stronger FY27 revenue growth. Investors should monitor management commentary and quarterly filings for updated guidance on Syngene International Q4 FY26 performance sustainability into FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_Syngene_International_Q4_FY26_compare_year_on_year\"><\/span><strong>How did Syngene International Q4 FY26 compare year on year?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Syngene International Q4 FY26 PAT of Rs 147.90 crore was lower 19.3 percent YoY. The year-on-year comparison for Syngene International Q4 FY26 versus Q4 FY25 is available in the official audited NSE and BSE exchange filings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_sector_does_Syngene_International_operate_in\"><\/span><strong>What sector does Syngene International operate in?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Syngene International operates in the Contract Research and CDMO sector in India and is listed on NSE and BSE. Syngene International Q4 FY26 results reflect the broader Contract Research and CDMO sector trends for the January to March 2026 quarter. Contextualising Syngene International Q4 performance within industry dynamics requires reviewing sector-level data alongside management commentary.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Syngene_International_a_good_investment_after_Q4_FY26_results\"><\/span><strong>Is Syngene International a good investment after Q4 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Whether Syngene International is a good investment after the Syngene International Q4 FY26 results depends on your individual financial goals, risk tolerance, and investment horizon. Syngene International Q4 FY26 results provide one data point on the company&#8217;s trajectory. Always consult a SEBI registered financial advisor before making any investment decision.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/torrent-power-q4-results-2026-2\">Torrent Power Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/usha-martin-q4-results-2026\">Usha Martin Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/triveni-engineering-and-industries-q4-results-2026\">Triveni Engineering and Industries Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/utkarsh-small-finance-bank-q4-results-2026\">Utkarsh Small Finance Bank Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/venus-pipes-and-tubes-q4-results-2026\">Venus Pipes and Tubes Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Syngene International Q4 FY26 results April 29, 2026: PAT Rs 147.90 crore, down 19.3% YoY. Revenue, analysis, management outlook and investor FAQs covered.<\/p>\n","protected":false},"author":28,"featured_media":80811,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858],"class_list":["post-80765","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1777621666:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["67"],"rank_math_title":["Syngene International Q4 FY26: PAT Rs 147.9 Cr Down 19.3%"],"rank_math_description":["Syngene International Q4 FY26 results April 29 2026: PAT Rs 147.90 crore, lower 19.3 percent YoY. Revenue, highlights, FAQs and analysis Full Q4 FY26 breakdown. April 29"],"rank_math_focus_keyword":["Syngene International Q4"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["80811"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["9994"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/01131703\/Syngene-International-Q4-FY26-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/80765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=80765"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/80765\/revisions"}],"predecessor-version":[{"id":80812,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/80765\/revisions\/80812"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/80811"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=80765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=80765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=80765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}